Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.40 |
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123704 | 0.89 | CYP3A4 (0.39) | CA1CA2CYP3A4CYP1A1CYP2D6 | |
| SCHEMBL18123782 | 0.89 | CYP3A4 (0.39) | CA1CA2CYP3A4CYP1A1CYP2D6 | |
| SCHEMBL18123778 | 0.88 | CYP3A4 (0.41) | CA1CA2CYP3A4CYP1A1CYP2D6 | |
| SCHEMBL20089227 | 0.85 | HTR4 (0.33) | — | |
| SCHEMBL18123826 | 0.84 | CTSK (0.40) | NPSR1MAPT | |
| SCHEMBL29879880 | 0.83 | CTSK (0.39) | NPSR1MAPT | |
| SCHEMBL20089231 | 0.83 | CTSK (0.39) | NPSR1MAPT | |
| SCHEMBL18867274 | 0.82 | HPGD (0.43) | IDO1MAPTBCHECNR2 | |
| SCHEMBL20089225 | 0.82 | TSHR (0.40) | CYP3A4NPSR1MAPTCNR2 | |
| SCHEMBL18123768 | 0.82 | LTA4H (0.41) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180111914-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| WO-2016157052-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | CA1 640/4885CA2 629/4885CA12 598/4885 |
| US-20180111914-A1 | WATER-SOLUBLE PRODRUGS | NR0B2, NR0B1, AVPR1B | CA1 599/4885CA2 811/4885CA12 521/4885 |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | CA1 640/4885CA2 629/4885CA12 598/4885 |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | CA1 640/4885CA2 629/4885CA12 598/4885 |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | CA1 640/4885CA2 629/4885CA12 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.